IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin

Vaccine

Volumn 19, Issue 1, 2000, Pages 75-85

  Fontana, Maria Rita ^a   Monaci, Elisabetta ^a   Yanqing, Liu ^b   Guoming, Qi ^b   Duan, Guangcai ^b   Rappuoli, Rino ^a   Pizza, Mariagrazia ^a  

^a CHIRON VACCINES   (Italy)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

CT mutants; NirB promoter; V. cholerae attenuated strain

Indexed keywords

BACTERIUM ANTIBODY; CHOLERA TOXIN; CHOLERA VACCINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBODY PRODUCTION; ARTICLE; CHOLERA; DETOXIFICATION; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; IMMUNOGENICITY; MICROBIAL ATTENUATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; VIBRIO CHOLERAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED C57BL; MUTATION; PROMOTER REGIONS (GENETICS); RABBITS; VACCINES, ATTENUATED; VIBRIO CHOLERAE;

EID: 0034663518     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00137-7     Document Type: Article

References (49)

1. Global programme for vaccines and immunization. 1998;WHO, Geneva.
2. Field M., Rao M.C., Chang E.B. Intestinal electrolyte transport and diarrheal disease. N. Engl. J. Med. 321:1989;800-806.
3. Pizza M., Masignani V., Rappuoli R. Molecular, functional and evolutionary aspects of ADP-ribosylating toxins. Alouf J., Freer J. The comprehensive sourcebook of bacterial protein toxins. 2nd ed. 1999;45-72 Academic Press, New York.
4. Mekalanos J.J., Swartz D.J., Pearson G.D., Harford N., Groyne F., de Wilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature. 306:1983;551-557.
5. Sixma T.K., Pronk S.E., Kalk K.H., Wartna E.S., van Zanten B.A., Witholt B., Hol W.G. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature. 351:1991;371-377.
6. Sixma T.K., Kalk K.H., Vanzanten B.A.M., Dauter Z., Kingma J., Witholt B., Hol W.G.J. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Mol. Biol. 230:1993;890-918.
7. Holmgren J., Lonnroth I., Svennerholm L. Tissue receptor for cholera exotoxin: postulated structure from studies with GM1-ganglioside and related glycolipids. Infect. Immun. 8:1973;208-214.
8. Merritt E.A., Sarfaty S., Vandenakker F., Lhoir C., Martial J.A., Hol W.G.J. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 3:1994;166-175.
9. Gill D.M., Woolkalis M.J. Cholera toxin-catalyzed [32P]ADP-ribosylation of proteins. Methods Enzymol. 195:1991;267-280.
10. Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature. 292:1981;413-417.
11. Moss J., Vaughan M. ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. Adv. Enzymol. Relat. Areas Mol. Biol. 61:1988;303-379.
12. Levine M.M., Black R.E., Clements M.L., Cisneros L., Nalin D.R., Young C.R. Duration of infection-derived immunity to cholera. J. Infect. Dis. 143:1981;818-820.
13. Karaolis D.K.R., Johnson J.A., Bailey C.C., Boedeker E.C., Kaper J.B., Reeves P.R. A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc. Natl Acad. Sci. USA. 95:1998;3134-3139.
14. Kimsey H.H., Waldor M. CTXΦ immunity: application in the development of cholera vaccines. Proc. Natl Acad. Sci. USA. 95:1998;7035-7039.
15. Waldor M.K., Mekalanos J.J. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science. 272:1996;1910-1914.
16. Waldor M.K., Rubin E.J., Pearson G.D.N., Kimsey H., Mekalanos J.J. Regulation, replication, and integration functions of the Vibrio cholerae CTXΦ are encoded by region RS2. Mol. Microbiol. 24:1997;917-926.
17. Splanger B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:1992;622-647.
18. Svennerholm A.M., Sack D.A., Holmgren J., Bardhan P.K. Intestinal antibody responses after immunisation with cholera B subunit. Lancet. I:1982;305-308.
19. Owen R.L., Pierce N.F., Apple R.T., Cray W.C. Jr. M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's Patches: a mechanism for antigen sampling and for microbial transepithelial migration. J. Infect. Dis. 153:1986;1108-1118.
20. Kerneis S., Bogdanova A., Kraehenbuhl J.P., Pringault E. Conversion by Peyer's patches lymphocytes of human enterocytes into M cells that transport bacteria. Science. 277:1997;949-952.
21. Holmgren J., Svennerholm A.M., Clemens J., Sack D., Black R., Levine M. An oral B subunit-whole cell vaccine against cholera: from concept to successful field trial. Adv. Exp. Med. Biol. 216B:1987;1649-1660.
22. Holmgren J., Svennerholm A.M., Jertborn M., Clemens J., Sack D.A., Salenstedt R., Wigzell H. An oral B subunit-whole cell vaccine against cholera. Vaccine. 10:1992;911-994.
23. Svennerholm A.M., Holmgren J. Oral combined B subunit-whole cell cholera vaccine. Holmgren J., Lindberg A., Möllby R. Development of vaccines and drugs against diarrhea. Eleventh Nobel Conference, Stockholm 1985. 1986;33-43 Studentlitteratur, Lund, Sweden.
24. Ketley J.M., Michalski J., Galen J., Levine M.M., Kaper J.B. Construction of genetically-marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett. 111:1993;15-22.
25. Levine M.M., Herrington D., Losonsky G., Tall B., Kaper J.B., Ketley J., Tacket C.O., Cryz S. Safety, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. I:1988;467-470.
26. Simanjuntak C.H., Ohanley P., Punjabi N.H., Noriega F., Pazzaglia G., Dykstra P., Kay B., Suharyono, Budiarso A., Rifai A.R., Wasserman S.S., Losonsky G., Kaper J., Cryz S., Levine M.M. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD-103-HgR in 24-month-old to 59-month-old Indonesian children. J. Infect. Dis. 168:1993;1169-1176.
27. Burnette W.N., Mar V.L., Platler B.W., Schlotterbeck J.D., McGinley M.D., Stoney K.S., Rohde M.F., Kaslow H.R. Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity. Infect. Immun. 59:1991;4266-4270.
28. Glineur C., Locht C. Importance of ADP-ribosylation in the morphological changes of PC12 cells induced by cholera toxin. Infect. Immun. 62:1994;4176-4185.
29. Hase C.C., Thai L.S., Boesmanfinkelstein M., Mar V.L., Burnette W.N., Kaslow H.R., Stevens L.A., Moss J., Finkelstein R.A. Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs. Infect. Immun. 62:1994;3051-3057.
30. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Yamamoto M., Fujihashi K., Van Ginkel F.W., Noda M., Takeda Y., McGhee J.R. A non toxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl Acad. Sci. USA. 94:1997;5267-5272.
31. Fontana M.R., Manetti R., Giannelli V., Magagnoli C., Marchini A., Olivieri R., Domenighini M., Rappuoli R., Pizza M. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:1995;2356-2360.
32. Liu Y.Q., Qi G.M., Xang S.X., Yu Y.M., Duan G.C., Zhang L.J., Gao S.Y. A natural vaccine candidate strain against cholera. Biomed. Environ. Sci. 8:1995;350-358.
33. Douce G., Fontana M.R., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:1997;2821-2828.
34. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning. A laboratory manual. 1989;Cold Spring Harbor Laboratory Press.
35. Goldberg M.B., Bokyo S.A., Calderwood S.B. Positive transcriptional regulation of an iron-regulated virulence gene in Vibrio cholerae. Proc. Natl Acad. Sci. USA. 88:1991;1125-1129.
36. Donnenberg M.S., Kaper J.K. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59:1991;4310-4317.
37. Lai C., Cancedda F., Duffy L.K. ADP-ribosyltranferase activity of Cholera toxin polypeptide A1 and the effect of limited trypsinolysis. Biochem. Biophys. Res. Commun. 102:1981;1021-1027.
38. Donta S.T., Moon H.W., Whipp S.C. Detection and use of heat-labile Escherichia coli enterotoxin with the use of adrenal cells in tissue culture. Science. 183:1973;334-335.
39. De S.N. Enterotoxicity of bacteria-free culture filtrate of Vibrio cholerae. Nature. 183:1959;1533-1534.
40. Dente L., Cesareni G., Cortese R. pEMBL: a new family of single stranded plasmids. Nucleic Acids Res. 11:1983;1645-1655.
41. Chen I., Finn T.M., Liu Y.Q., Qi G.M., Rappuoli R., Pizza M. A recombinant live-attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infect. Immun. 66:1998;1648-1653.
42. DiRita V.J. Co-ordinate expression of virulence genes by ToxR in Vibrio cholerae. Mol. Microbiol. 6:1992;451-458.
43. Oxer M.D., Bentley C.M., Doyle J.G., Peakman T.C., Charles I.G., Makoff A.J. High level heterologous expression in E. coli using the anaerobically-activated nirB promoter. Nucleic Acids Res. 19:1991;2889-2892.
44. Booth B., Boesman-Finkelstein M., Finkelstein R. Vibrio cholerae Hemagglutinin/protease nicks cholera enterotoxin. Infect. Immun. 45:1984;558-560.
45. Svennerholm A.M., Holmgren J. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect. Immun. 13:1976;735-740.
46. Black R.E., Levine M.M., Clements M.L., Young C.R., Svennerholm A.M., Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun. 55:1987;1116-1120.
47. Clemens JD, Harris JR, Sack DA, Chakraborty J, Ahmed F, Stanton BF, Khan MU, Kay BA, Huda N, Khan MR, Yunus M, Rao MR, Svennerholm AM, Holmgren J, Field trial of oral cholera vaccines in Bangladesh: results of one year follow-up, J. Infect. Dis. 1988;15860-9.
48. Clemens J.D., Sack D., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., Huda N., Khan M.U., Kay B.A., Khan M.R., Ansaruzzaman M., Yunus M., Rao M.R., Svennerholm A.M., Holmgren J. Cross protection by B subunit-whole cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158:1988;372-377.
49. Finkelstein R.A. Cholera enterotoxin (choleragen): a historical perspective [ed]Baru D, Greenough WB III. Current topics in infectious diseases: Cholera. 1992;155-185 Plenum Medical Publisher, New York.